Telemedicine Co. Surges on Revenue News
Source: Streetwise Reports  (11/4/22)
As internet-enabled health care becomes more accepted in the wake of the pandemic, telemedicine company Reliq Health Technologies Inc. is seeing its revenue soar. More >

San Diego Co. Signs US$4.2B Deal To Develop mRNA Vaccines
Source: Streetwise Reports  (11/3/22)
Arcturus Therapeutics Holdings Inc. shares traded 19% higher yesterday after the firm reported it entered a global partnership with CSL Seqirus to develop and commercialize self-amplifying mRNA vaccines worldwide. More >

Pharma Co. Earns Big Rewards from Global License Deal
Source: Streetwise Reports  (11/2/22)
Kiniksa Pharmaceuticals Ltd. shares traded 12% higher yesterday after the company reported Q3/22 financial results that included a 720% YoY increase in net revenue attributed to a combination of organic growth and increases in global licensing revenue. More >

Biopharma Co. Trades 39% Higher
Source: Streetwise Reports  (11/1/22)
Actinium Pharmaceuticals Inc. shares traded 39% higher yesterday to a new 52-week high after the firm reported topline data from its Phase 3 SIERRA study of Iomab-B in patients with active relapsed or refractory acute myeloid leukemia. During the pivotal trial, Iomab-B met its primary pre-established endpoint of durable complete remission or dCR of six months post-initial remission following a bone marrow transplant. More >

Biopharma Gains Two Cancer Cell Therapy Programs and a Target Price 10 Times Current
  (10/31/22)
This developer of cancer immunotherapies will take possession of these clinical-stage assets in a transaction with GSK and subsequently advance them toward approval, noted a ROTH Capital Partners report. More >

Biotech Co. Achieves High ORRs in Ph. 1 NSCLC Trial
Source: Streetwise Reports  (10/28/22)
Shares of Nuvalent Inc. traded 60% higher to a new 52-week intraday high after the company reported initial data from its Phase 1 ARROS-1 trial of NVL-520 demonstrating positive objective response rates in patients with ROS1-Positive non-small cell lung cancer. More >

Potential ROI With German Biopharma Co. Notable
Source: Dr. Elemer Piros  (10/27/22)
This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report. More >

CRO Firm's Shares Rise on Q3 Earnings and Growth Prospects
Source: Streetwise Reports  (10/26/22)
Shares of full-service clinical contract research organization Medpace Holdings Inc. traded 37% higher yesterday after the company reported Q3/22 financial results that included a nearly 30% YoY increase in revenue. More >

Vaccine Co. Posts Positive Ph. 1/2 IPD Trial Results
Source: Streetwise Reports  (10/25/22)
Shares of Vaxcyte Inc. traded 61% higher yesterday to a new 52-week high after the company reported positive topline results from its Phase 1/2 study of VAX-24, its novel 24-valent pneumococcal conjugate vaccine candidate being developed to prevent invasive pneumococcal disease in adults 18 to 64 years of age. More >

Expert Says Buy Pharma Co. Stock 'as Soon as Possible'
Source: Clive Maund  (10/25/22)
Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy its stock. More >

Biopharma Co. Shows Large Potential Return
Source: Dr. Joseph Pantginis   (10/21/22)
Palatin Technologies Inc.'s third-party clinical trial of Vyleesi in women with hypoactive sexual desire disorder was just published in the Journal of Clinical Investigation, and the biopharma offers investors significant potential return, noted an H.C. Wainwright & Co. report. More >

Robotic Surgical Device Co.'s Shares Rise on Q3 Earnings
Source: Streetwise Reports  (10/20/22)
Shares of Intuitive Surgical Inc. traded 9% higher yesterday after the robotic surgical device maker reported Q3/22 earnings that included an 11% YoY increase in revenue and a 13% YoY increase in its installed da Vinci Surgical System base. More >

Companies Use Blockchain To Connect Hemp Growers, Consumers
Source: Streetwise Reports  (10/19/22)
Industrial hemp is legal in all 50 states, and companies are working to get CBD, insulation, textiles, and biofuel made from it to the masses. These three companies hope their partnership will help connect the growers and buyers. More >

Biotech Co.'s Target Price Over Three Times Current
Source: Dr. Joseph Pantginis   (10/13/22)
Expanded interim data from the Phase 2 trial of this biotech's lead asset PDS0101 in HPV16-associated cancers are consistent with previously reported results from the same study. Read more to discover why H.C Wainright & Co. believes this stock is a Buy with a target price over three times the current. More >

Biopharma Co. Partners With Merck for Combo Drug Trial
Source: Dr. Joseph Pantginis  (10/12/22)
With this and other clinical studies, the U.S. company has a busy and, thus, catalyst-rich Q4/22 ahead, noted an H.C. Wainwright & Co. report. More >

Biopharma Co.'s Shares Roll to New 52-Week High Price
Source: Streetwise Reports  (10/12/22)
Shares of DICE Therapeutics Inc. traded 62% higher yesterday and established a new 52-week intraday high after the company reported positive topline data from its Phase 1 DC-806 Psoriasis study. More >

Chen Reveals His Picks for Last Quarter
Source: Streetwise Reports  (10/11/22)
Asset manager Chen Lin's picks for the home stretch of 2022 include several biotechs and some precious metals companies. More >

US Firm Teams up With Leading Pharma Co. To Delay T1D Onset
Source: Streetwise Reports  (10/7/22)
Provention Bio Inc.'s shares traded 25% higher yesterday after the company reported it is joining forces with Sanofi U.S. to support the potential upcoming U.S. launch of its teplizumab for use in delaying the onset of clinical type 1 diabetes in at-risk patients. The U.S. FDA is expected to rule on the firm's Biologics License Application in mid-November 2022. More >

Biopharma Target Price 10 Times Current
Source: Dr. Elemer Piros  (10/6/22)
Read to learn why ROTH Capital Partners gave Atai Life Sciences NV a Buy rating and a target price 10 times its current. More >

Biotech Co.'s Drug Showing 'Early Signs of Benefit'
Source: Dr. Elemer Piros  (10/6/22)
With this upcoming analysis, the board will determine whether the Phase 2b/3 trial may continue to completion, noted a ROTH Capital Partners report. More >

Trial Results of New Drug for An Eye Disease 'Encouraging'
Source: Dr. Yale Jen  (10/6/22)
The data suggest this treatment could be safer and more effective in treating proliferative vitreoretinopathy than compounded methotrexate, noted a Laidlaw & Co. report. More >

Co. Uses RNA Editing as Treatment for Rare Disease
Source: Andrew Fein  (10/3/22)
The firm plans to advance its alpha-1 antitrypsin deficiency program into the clinic next year, noted an H.C. Wainwright & Co. report. More >

Interim Results From Phase 2b Trial Are 'Encouraging'
Source: Dr. Elemer Piros  (9/30/22)
Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report. More >

Biopharma Co. Awarded FDA Clearance for Advanced Solid Tumors Trial
Source: Streetwise Reports  (9/30/22)
Shares of oncology-focused biopharmaceutical company Immuneering Corp. traded 9% higher after the firm reported it received U.S. FDA clearance for its IND Application for a Phase 1/2a clinical trial of IMM-1-104 for use in treatment of advanced solid tumors with RAS mutations. The company expects to enroll the first patient in the study in Q4/22. More >

Pharma Co. Meets Primary Endpoint in Phase 3 Alzheimer's Trial
Source: Streetwise Reports  (9/29/22)
Shares of Eisai Co. Ltd. traded 58% higher yesterday after the company reported topline data from its global Phase 3 clinical study demonstrating that its lecanemab significantly met the primary and key secondary endpoints in reducing mild cognitive impairment due to Alzheimer's disease. More >